599 related articles for article (PubMed ID: 30880070)
21. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
22. Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma.
Mehra R; Nallandhighal S; Cotta B; Knuth Z; Su F; Kasputis A; Zhang Y; Wang R; Cao X; Udager AM; Dhanasekaran SM; Cieslik MP; Morgan TM; Salami SS
JCO Precis Oncol; 2024 May; 8():e2300565. PubMed ID: 38810179
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of a gene signature in clear cell renal cell carcinoma.
Chen L; Luo Y; Wang G; Qian K; Qian G; Wu CL; Dan HC; Wang X; Xiao Y
J Cell Physiol; 2019 Jul; 234(7):10324-10335. PubMed ID: 30417359
[TBL] [Abstract][Full Text] [Related]
24. β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
Liu Y; Liu H; Liu W; Zhang W; An H; Xu J
World J Urol; 2015 Nov; 33(11):1791-9. PubMed ID: 25630622
[TBL] [Abstract][Full Text] [Related]
25. Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study.
Wu S; Hong G; Xu A; Zeng H; Chen X; Wang Y; Luo Y; Wu P; Liu C; Jiang N; Dang Q; Yang C; Liu B; Shen R; Chen Z; Liao C; Lin Z; Wang J; Lin T
Lancet Oncol; 2023 Apr; 24(4):360-370. PubMed ID: 36893772
[TBL] [Abstract][Full Text] [Related]
26. Commentary on "Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study." Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, Choueiri TK, Dana-Farber Cancer Institute, Boston, MA 02115.: Lancet Oncol 2013;14(1):81-87. [Epub 2012 Dec 7]. doi: 10.1016/S1470-2045(12)70517-X. Erratum in, Lancet Oncol 2013;14(3):e89.
Meng M
Urol Oncol; 2014 May; 32(4):512-3. PubMed ID: 24767687
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma.
Haddad AQ; Luo JH; Krabbe LM; Darwish O; Gayed B; Youssef R; Kapur P; Rakheja D; Lotan Y; Sagalowsky A; Margulis V
BJU Int; 2017 May; 119(5):741-747. PubMed ID: 28075543
[TBL] [Abstract][Full Text] [Related]
28. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
29. Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study.
Jiang Y; Liang X; Han Z; Wang W; Xi S; Li T; Chen C; Yuan Q; Li N; Yu J; Xie Y; Xu Y; Zhou Z; Poultsides GA; Li G; Li R
Lancet Digit Health; 2021 Jun; 3(6):e371-e382. PubMed ID: 34045003
[TBL] [Abstract][Full Text] [Related]
30. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
31. An integrated nomogram combining lncRNAs classifier and clinicopathologic factors to predict the recurrence of head and neck squamous cell carcinoma.
Cui J; Wen Q; Tan X; Piao J; Zhang Q; Wang Q; He L; Wang Y; Chen Z; Liu G
Sci Rep; 2019 Nov; 9(1):17460. PubMed ID: 31767907
[TBL] [Abstract][Full Text] [Related]
32. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
Boorjian S
Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
[TBL] [Abstract][Full Text] [Related]
33. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
[TBL] [Abstract][Full Text] [Related]
34. Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.
El-Mokadem I; Fitzpatrick J; Bondad J; Rauchhaus P; Cunningham J; Pratt N; Fleming S; Nabi G
Br J Cancer; 2014 Sep; 111(7):1381-90. PubMed ID: 25137021
[TBL] [Abstract][Full Text] [Related]
35. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma.
Wei JH; Haddad A; Wu KJ; Zhao HW; Kapur P; Zhang ZL; Zhao LY; Chen ZH; Zhou YY; Zhou JC; Wang B; Yu YH; Cai MY; Xie D; Liao B; Li CX; Li PX; Wang ZR; Zhou FJ; Shi L; Liu QZ; Gao ZL; He DL; Chen W; Hsieh JT; Li QZ; Margulis V; Luo JH
Nat Commun; 2015 Oct; 6():8699. PubMed ID: 26515236
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
37. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.
White-Al Habeeb NM; Di Meo A; Scorilas A; Rotondo F; Masui O; Seivwright A; Gabril M; Girgis AH; Jewett MA; Yousef GM
Clin Exp Metastasis; 2015 Aug; 32(6):531-41. PubMed ID: 26037892
[TBL] [Abstract][Full Text] [Related]
38. p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models.
Morshaeuser L; May M; Burger M; Otto W; Hutterer GC; Pichler M; Klatte T; Wild P; Buser L; Brookman-May S
Urol Oncol; 2018 Mar; 36(3):94.e15-94.e21. PubMed ID: 29221641
[TBL] [Abstract][Full Text] [Related]
39. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
40. Integration of NRP1, RGS5, and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma.
Yoshida T; Ohe C; Ikeda J; Atsumi N; Saito R; Taniguchi H; Ohsugi H; Sugi M; Tsuta K; Matsuda T; Kinoshita H
J Pathol Clin Res; 2021 Nov; 7(6):590-603. PubMed ID: 34212534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
